Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NUV-868 + enzalutamide
- Development stage
- Unknown
- Lead developer
- Nuvation Bio
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
NUV-868 + enzalutamide is an oral combination therapy under investigation for the treatment of advanced solid tumors, particularly metastatic castration-resistant prostate cancer (mCRPC). NUV-868 is a BD2-selective BET (bromodomain and extra-terminal domain) inhibitor, which targets epigenetic regulators such as BRD4, thereby modulating genes that control tumor growth and differentiation. Enzalutamide is an androgen receptor inhibitor that blocks the androgen receptor signaling pathway, which is critical for the progression of prostate cancer. The combination is being studied to address tumor resistance mechanisms and potentially deliver synergistic antitumor activity by targeting both epigenetic and androgen receptor-driven growth pathways[1][3][5][7].
- Other names
- enzalutamide
02
Targets
Bromodomain-containing protein 4, second bromodomainAR (Adrenergic receptors)
Beyond the preview
Go deeper on NUV-868 + enzalutamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NUV-868 + enzalutamide.